Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.

Stantial, Nicole; Rogojina, Anna; Gilbertson, Matthew; Sun, Yilun; Miles, Hannah; Shaltz, Samantha; Berger, James; Nitiss, Karin C et al. · Proc Natl Acad Sci U S A · 2020

basic_science · Level V

Where this comes from

Abstract

Topoisomerase II (Top2) is an essential enzyme that resolves catenanes between sister chromatids as well as supercoils associated with the over- or under-winding of duplex DNA. Top2 alters DNA topology by making a double-strand break (DSB) in DNA and passing an intact duplex through the break. Each component monomer of the Top2 homodimer nicks one of the DNA strands and forms a covalent phosphotyrosyl bond with the 5' end. Stabilization of this intermediate by chemotherapeutic drugs such as etoposide leads to persistent and potentially toxic DSBs. We describe the isolation of a yeast <i>top2</i> mutant (<i>top2-F1025Y,R1128G</i>) the product of which generates a stabilized cleavage intermediate in vitro. In yeast cells, overexpression of the <i>top2-F1025Y,R1128G</i> allele is associated with a mutation signature that is characterized by de novo duplications of DNA sequence that depend on the nonhomologous end-joining pathway of DSB repair. Top2-associated duplications are promoted by the clean removal of the enzyme from DNA ends and are suppressed when the protein is removed as part of an oligonucleotide. <i>TOP2</i> cells treated with etoposide exhibit the same mutation signature, as do cells that overexpress the wild-type protein. These results have implications for genome evolution and are relevant to the clinical use of chemotherapeutic drugs that target Top2.

Medical subject headings